Efficacy, Safety, and Biomarkers of Neoadjuvant Dalpiciclib (CDK4/6 inhibitor) plus Aromatase Inhibitors in Operable HER2-Negative Luminal B Breast Cancer: A Prospective, Single-Center, Single-Arm, Phase II Trial (DANCER)
新辅助达匹西利(CDK4/6 抑制剂)联合芳香化酶抑制剂治疗可手术 HER2 阴性 Luminal B 型乳腺癌的疗效、安全性和生物标志物:一项前瞻性、单中心、单臂 II 期试验 (DANCER)
期刊:MedComm
影响因子:10.7
doi:10.1002/mco2.70402
Zhou, Yunxiang; Zhang, Zhiyun; Chen, Huihui; Huang, Fengbo; Shen, Lu; Tao, Siqi; Qian, Wei; Hong, Hui; Pan, Chi; Wang, Ze; Zhang, Jiao; Hu, Yue; Shen, Yong; Fu, Jun; Mao, Weikang; Wu, Shijie; Guo, Xianan; Wang, Hui; Ma, Mindi; Ma, Ting; Pan, Liqiang; Chen, Yiding